ArticleSurgical neurology international2026
Quality of life and outcomes of patients operated on for glioblastoma.
Article in Surgical neurology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glioblastoma is the most common and aggressive primary malignant brain tumor in adults, with a poor prognosis despite multimodal treatment. This study aimed to describe the diagnostic aspects, therapeutic strategies, quality of life (QoL), and outcomes of patients operated on for glioblastoma at the Yaoundé General Hospital. Methods: This was a retrospective cohort study conducted at the Yaoundé General Hospital. Included were 32 patients who underwent surgery for glioblastoma with histological evidence from January 2018 to June 2025. Data were collected from medical records and analyzed using the Statistical Packages for the Social Sciences version 20. Comparisons between groups were performed using the Chi-square test or Student's t-test as appropriate. Survival distributions were compared using the Kaplan-Meier method and the log-rank test. Statistical significance was set at Results: Thirty-two patients were included, with a median age of 47.50 years (17.75; 59.75), a mean age of 42.9 ± 13.8 years, and a female predominance (65.6%). The most common presenting symptom was neurologic deficit (68.8%). Magnetic resonance imaging was the main diagnostic modality (59.4%), and the tumor was most often located in the temporal lobe (30.8%). Surgery alone was performed in 56.3% of cases, whereas 25% received surgery followed by radiochemotherapy. The average overall survival was 10.2 months, increasing to 13.4 months in patients who received the full multimodal treatment. QoL scores were also better in this group. Age >60 was found to be significantly associated with poor outcomes. Conclusion: Glioblastoma affects all ages in our setting. Combined therapeutic strategies, especially the addition of radiochemotherapy after surgery, were associated with longer survival and better QoL. Multidisciplinary management remains essential to improve outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.